chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 16.0
Sex: F
Vaccine: HPV4
Symptoms: Exposure during pregnancy
Clinical narrative: This spontaneous prospective pregnancy report as received from a certified medical assistant refers to a 16 years old female patient with none pertinent medical history and none drug reactions/allergies. On 05-NOV-2013 the patient was vaccinated with the first dose of GARDASIL lot # J008423, expiry date 21-JAN-2016, 0.5 ml, intramuscularly. The patient was pregnant with last menstrual period of 31-MAR-2013 and estimated due date of 05-JAN-2014. Initial exposure to GARDASIL was at 31 weeks. There were no lab diagnostics studies performed. The pregnancy outcome was outcome pending. The patient's outcome was unknown, also reported as not recovered. No additional doses of GARDASIL were administered. Additional information has been requested.
Age: 12.0
Sex: F
Vaccine: HEP
Symptoms: Inappropriate schedule of drug administration, No adverse event
Clinical narrative: This spontaneous report as received from a registered nurse refers to a female patient of 12 years old with no reported medical history. On June 2009 the patient was vaccinated with hepatitis B vaccine (manufacturer unknown) dose 1 (exact date, route, dose and lot number unknown, RECOMBIVAX could not be ruled out). On July 2009 the patient was vaccinated with hepatitis B (manufacturer unknown) dose 2 (exact date, route, dose and lot number unknown). On August 2009 the patient was vaccinated with hepatitis B vaccine (manufacturer unknown) dose 3 (exact date, route, dose and lot number unknown). On August 2009 the patient experienced received first dose on 06/2009, 2nd dose on 07/2009 and third on 08/2009 (Inappropriate schedule of vaccine administered). The nurse also reports that this patient received an unspecified HPV vaccine, GARDASIL could not be ruled out, on June 2009, the 2nd dose on July/2009 and the third on October 2009. This case was linked to 1303USA013867 (same reporter link). Follow up was received from the same registered nurse reporting that there was no adverse effect, no adverse information updated to her. Additional information is not expected.
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a health department nurse refers to a patient who was administered received a dose of VARIVAX (Merck) (lot # 671162/1207AA, exp date: 26-JUL-2013) (which was stored at an average temperature of 8F-14F for six months) on 02-JUL-2013. No adverse effects reported. Nurse practitioner stated the facility made the decision on their own to revaccinate their patients and declined having this SR sent to GVS for evaluation. This is one of several reports received from the same source (linked case # 1312USA007988 and 1312USA012254). Additional information has been requested.
Age: 61.0
Sex: M
Vaccine: VARZOS
Symptoms: Condition aggravated, Musculoskeletal pain
Clinical narrative: This spontaneous report was received from the physician and refers to a 61 year old male patient with chronic shoulder pain, allergy to aspirin and allergy to LIPITOR. On 15-NOV-2013, the patient was vaccinated with ZOSTAVAX (lot # and expiration date, dose were not reported). Concomitant therapies included VICODIN, ibuprofen, BENICAR, LEXAPRO, amlodipine, tramadol hydrochloride, testosterone, PREVACID, diazepam (manufacturer unknown) and ADDERALL tablets. The patient with pre-existing and chronic shoulder pain prior to receiving ZOSTAVAX needed to receive a localized steroid injection following the administration of ZOSTAVAX which was performed on 15-NOV-2013. The patient was given VICODIN, ibuprofen for the treatment of adverse event. No lab diagnostics studies were performed. The patient sought medical attention, he had office visit. The outcome of needs to receive a localized steroid injection was reported as not recovered/not resolved at the time of the event. The relatedness between ZOSTAVAX and the adverse event was unknown at the time of the event. Additional information has been requested.
Age: 1.0
Sex: F
Vaccine: VARCEL
Symptoms: Herpes zoster
Clinical narrative: This spontaneous report as received from a licensed vocational nurse refers to a 4 year old female patient. Pertinent medical history, drug reactions or allergies were not reported. On 08-DEC-2010, the patient was vaccinated with VARIVAX (Merck) (dose, route and lot # were not reported). Concomitant medication was not reported. On 25-DEC-2013, the patient who previously received VARIVAX (Merck), subsequentially developed shingles. The patient was seen in a urgent care facility for treatment. The patient was treated with acyclovir. The patient's present status was reported as recovering. Causality was not reported. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to multiple patients of unknown demographics.  On an unknown date in 2013 the patient was vaccinated with MMR II. The medical assistant reported that, multiple unspecified patients were administered with MMR II that was exposed to unspecified temperature excursions from January 2013 to the present. No adverse effects were reported. This case is linked to 1401USA000055, 1401USA000056, 1312USA012478 (same reporter). Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to multiple patients of unknown demographics. On an unknown date in 2013 the patient was vaccinated with PNEUMOVAX 23. The medical assistant reported that, multiple unspecified patients were administered with PNEUMOVAX 23 that was exposed to unspecified temperature excursions from January 2013 to the present. No adverse effects were reported. This case is linked to 1401USA000054, 1401USA000055, 1312USA012478 (same reporter). Additional information has been requested.
Sex: U
Vaccine: HEP
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to multiple patients of unknown demographics.  On an unknown date in 2013 the patient was vaccinated with RECOMBIVAX HB. The medical assistant reported that, multiple unspecified patients were administered with RECOMBIVAX HB that was exposed to unspecified temperature excursions from January 2013 to the present. No adverse effects were reported. This case is linked to 1401USA000054, 1401USA000056, 1312USA012478 (same reporter). Additional information has been requested.
Age: 7.0
Sex: F
Vaccine: HPV4
Symptoms: No adverse event, Wrong drug administered
Clinical narrative: This spontaneous report as received from a registered nurse refers to a 7 year old female patient. On 18-DEC-2013 the patient was vaccinated with GARDSIL (lot # J012212, exp date 18-FEB-2016), 0.5 ml, intramuscular. The nurse reported that patient received GARDASIL, meant for her older sister, in place of flu vaccine. No adverse effect. Additional information has been requested.
Sex: M
Vaccine: HPV4
Symptoms: Injection site pain
Clinical narrative: This spontaneous report as received from a consumer via a company representative refers to the consumer's son, a male patient of unknown age. On an unknown date the patient was vaccinated with third dose of GARDASIL (lot #, expiration date, dose, route not reported) for prevention of human papillomavirus (HPV). On an unknown date the patient felt pain at the injection site that went through his body after administration. The patient did not seek medical attention. The outcome of the events was reported as resolved on an unspecified date. Additional information has been requested.
Age: 24.0
Sex: F
Vaccine: HPV4
Symptoms: Human chorionic gonadotropin positive, Ovarian germ cell teratoma benign, Subchorionic haemorrhage, Ultrasound antenatal screen abnormal
Clinical narrative: Information has been received from a medical assistant, for GARDASIL, a Pregnancy Registry product, concerning a 24 years old female patient with drug hypersensitivity to penicillin and a family history of breast cancer who on an unspecified dates was vaccinated with the first and second dose of GARDASIL at another unspecified provider's office. On 23-APR-2012 the patient was vaccinated in the medical assistant's office with a third dose of GARDASIL, (lot #: 671994/1537AA; exp date: 21-JUN-2014) 0.5 ml, intramuscular. Concomitant therapy included Prenatal vitamins. The patient was pregnant. No symptoms were noted. The patient's Last Menstrual Period (LMP) was on 05-APR-2012 and estimated delivery date (EDD) was on 10-JAN-2013. No treatment was given for the adverse event. Follow-up information has been received from a physician via an initial pregnancy questionnaire who reported that the 24-years-old female patient with asthma with no previous pregnancies was vaccinated with a third of GARDASIL, 0.5 ml, intramuscularly (Lot # 671994/1537AA). Concomitant therapies included: TRIPHASIL. The physician reported that on 11-JUN-2012 an ultrasound was performed which results were as follows: 8 weeks of pregnancy in Vitro Embryo Production (IVP) 2 cm, 2 cm, subchorionic bleed, ovarian dermoid. At the time of reporting, the patient's outcome from subchorionic bleed and ovarian dermoid was unknown. The relatedness between vaccination with GARDASIL and adverse events was not reported. Follow-up information was received and it was reported that the Estimate Delivery date was on 11-JAN-2013. The infant was normal and had no congenital anomaly. Additional information is not expected.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Arthralgia, Asthenia, Cough, Nausea, Upper-airway cough syndrome
Clinical narrative: 12/15 burning in joints. 12/16 nausea and vomiting. 12/17 post nasal drip, cough, wheezing with activity to 12/24 weakness, N/V and wheezing.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Vomiting, Wheezing
Clinical narrative: 12/15 burning in joints. 12/16 nausea and vomiting. 12/17 post nasal drip, cough, wheezing with activity to 12/24 weakness, N/V and wheezing.
Age: 49.0
Sex: M
Vaccine: FLU3, PPV, FLU3, PPV
Symptoms: Asthenia, Cardiac pacemaker insertion, Dysstasia, Hip fracture, Hypoaesthesia
Clinical narrative: Legs became numb and loss feeling, loss strength in legs, hands and arms. He couldn't stand up his legs would not hold him. He had blood treatments-suffered 5 or 6 heart attacks. Had to have a pace maker put in. Became paralyzed for the neck down. Broken hip.
Age: 49.0
Sex: M
Vaccine: FLU3, PPV, FLU3, PPV
Symptoms: Laboratory test, Muscular weakness, Myocardial infarction, Paralysis, Paraplegia
Clinical narrative: Legs became numb and loss feeling, loss strength in legs, hands and arms. He couldn't stand up his legs would not hold him. He had blood treatments-suffered 5 or 6 heart attacks. Had to have a pace maker put in. Became paralyzed for the neck down. Broken hip.
Age: 49.0
Sex: M
Vaccine: FLU3, PPV, FLU3, PPV
Symptoms: Sensory loss
Clinical narrative: Legs became numb and loss feeling, loss strength in legs, hands and arms. He couldn't stand up his legs would not hold him. He had blood treatments-suffered 5 or 6 heart attacks. Had to have a pace maker put in. Became paralyzed for the neck down. Broken hip.
Age: 49.0
Sex: M
Vaccine: FLU3, PPV, FLU3, PPV
Symptoms: Myocardial infarction, Paralysis, Sensory loss, Therapeutic procedure
Clinical narrative: Legs became numb and loss feeling, loss strength in legs, hands and arms. He couldn't stand up his legs would not hold him. He had blood treatments-suffered 5 or 6 heart attacks. Had to have a pace maker put in. Became paralyzed for the neck down. Broken hip.
Age: 0.16
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Alanine aminotransferase, Aspartate aminotransferase, Body temperature increased, Chest X-ray, Full blood count
Clinical narrative: "Significant rash" per provider dictation. Rectal temp 100.0 degrees F.
Age: 0.16
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Metabolic function test, Rash
Clinical narrative: "Significant rash" per provider dictation. Rectal temp 100.0 degrees F.
Age: 23.0
Sex: M
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: Redness and swelling at the site of received varicella vaccine.
Age: 73.0
Sex: M
Vaccine: FLU3, FLU3
Symptoms: Back pain, Hypoaesthesia, Muscular weakness, Musculoskeletal pain, Pain in extremity
Clinical narrative: Patient noted low back pain - over the course of weeks noted progressive lower extremity weakness associated with the low back pain which radiates to legs and across buttocks. 11/11/13 - numbness sensation in hands. Admitted to hospital 11/11/13 - 11/21/13. Re-admitted 11/27/13 - 12/4/13. Treated with plasmapheresis x 5 during first hosp stay. Treated with same x 5 during second hosp. stay.
Age: 73.0
Sex: M
Vaccine: FLU3, FLU3
Symptoms: Plasmapheresis
Clinical narrative: Patient noted low back pain - over the course of weeks noted progressive lower extremity weakness associated with the low back pain which radiates to legs and across buttocks. 11/11/13 - numbness sensation in hands. Admitted to hospital 11/11/13 - 11/21/13. Re-admitted 11/27/13 - 12/4/13. Treated with plasmapheresis x 5 during first hosp stay. Treated with same x 5 during second hosp. stay.
Age: 56.0
Sex: F
Vaccine: FLU3, MMR, TDAP, VARZOS
Symptoms: Asthma, Cough, Urticaria
Clinical narrative: Hives on both arms, trunk and rear; then asthma. Treated at hospital, coughing.
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Rash generalised
Clinical narrative: Rash head to toe.
Age: 32.0
Sex: F
Vaccine: FLU3
Symptoms: Pruritus, Skin reaction, Skin test, Urticaria
Clinical narrative: Broke out full body hives and itchiness, that has continued to this date. Doctor at hospital saw me and referred me to a dermatologist, and my own doctor has said this condition will last as long as histamine is in my system.  Where I am scratched/skin tested, there is an immediate reaction in the shape of the scratching.
Age: 53.0
Sex: F
Vaccine: HEP
Symptoms: Cough, Fatigue, Mobility decreased, Nausea, Pallor
Clinical narrative: 12/24/13=nausea, cough, felt rundown. 12/26/13=fever, pale,could not get out of bed. 1/2/2014=feeling better.
Age: 53.0
Sex: F
Vaccine: HEP
Symptoms: Pyrexia
Clinical narrative: 12/24/13=nausea, cough, felt rundown. 12/26/13=fever, pale,could not get out of bed. 1/2/2014=feeling better.
Age: 45.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Pain in extremity
Clinical narrative: This spontaneous report was received from a 45 year old female consumer referring on herself. Medical history and concurrent conditions were not reported. On 09-JUL-2013, the patient was vaccinated with the first dose of GARDASIL. Dose, route and lot number were not reported. On 05-SEP-2013 the patient received the second dose of GARDASIL. Dose, route and lot number were not reported. No co-suspect and concomitant therapies were reported. The patient reported that she developed a sore arm after her second vaccination with GARDASIL (approximately on 05-SEP-2013). The patient explained that her arm had felt sore since receiving this dose of the vaccine. The patient stated that only recently, some time in December 2013, had the arm begun to feel better. The patient also stated that she was unsure if would complete the series. The patient did not seek medical attention. The causality was not reported. Additional information has been requested.
Age: 45.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Injection site erythema, Injection site pain, Mobility decreased, Pain in extremity
Clinical narrative: This spontaneous report was received from a 45 year old female consumer referring on herself. Medical history and concurrent conditions were not reported. On 09-JUL-2013, the patient was vaccinated with the first dose of GARDASIL. Dose, route and lot number were not reported. On 05-SEP-2013 the patient received the second dose of GARDASIL. Dose, route and lot number were not reported. No co-suspect and concomitant therapies were reported. The patient reported that she developed a sore arm after her second vaccination with GARDASIL (approximately on 05-SEP-2013). The patient explained that her arm had felt sore since receiving this dose of the vaccine. The patient stated that only recently, some time in December 2013, had the arm begun to feel better. The patient also stated that she was unsure if would complete the series. The patient did not seek medical attention. The causality was not reported. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Hepatitis B virus test positive
Clinical narrative: This spontaneous report as received from a pharmacist refers to a male patient of unknown age. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot number not reported). The pharmacist stated that the patient had blood work completed on an unspecified date and the results of the blood work stated that the patient was positive for Hepatitis B. The patient had received ZOSTAVAX on an unspecified date prior to the blood work being completed. The outcome of the adverse event was unknown. Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: PPV
Symptoms: Chills, Erythema, Pain, Pyrexia, Skin papilloma
Clinical narrative: This spontaneous report was received from a pharmacist refers to a 65 year old female patient. On 03-DEC-2013, the patient was vaccinated with PNEUMOVAX 23 (dose and frequency was not reported) lot # J005071, intramuscular for vaccination. On an unknown date in December 2013, the patient experienced red, hot, swollen, taughtness of kin which was painful and sore. On an unknown date in December 2013, the patient also experienced fever and chills. The patient sought medical attention and visited an unknown primary healthcare provider. The patient was prescribed with unspecified oral antibiotics. The outcome of the event red, hot, swollen, taughtness of skin which was painful and sore and fever and chills was reported as recovered. Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: PPV
Symptoms: Skin tightness, Swelling
Clinical narrative: This spontaneous report was received from a pharmacist refers to a 65 year old female patient. On 03-DEC-2013, the patient was vaccinated with PNEUMOVAX 23 (dose and frequency was not reported) lot # J005071, intramuscular for vaccination. On an unknown date in December 2013, the patient experienced red, hot, swollen, taughtness of kin which was painful and sore. On an unknown date in December 2013, the patient also experienced fever and chills. The patient sought medical attention and visited an unknown primary healthcare provider. The patient was prescribed with unspecified oral antibiotics. The outcome of the event red, hot, swollen, taughtness of skin which was painful and sore and fever and chills was reported as recovered. Additional information has been requested.
Age: 57.0
Sex: M
Vaccine: FLU3, PPV
Symptoms: Dyspnoea, Vaccination site erythema, Vaccination site pruritus
Clinical narrative: Erythema and pruritus on upper arms B/L at site of vaccination. At 2015 rapid response team called as patient c/o increased breathing difficulty. Pt given IV BENADRYL and ZOFRAN.
Age: 64.0
Sex: M
Vaccine: VARZOS
Symptoms: Myalgia
Clinical narrative: Patient said he experienced muscle pain that moved around his body beginning the day he received the immunization. He still has this pain today.
Age: 20.0
Sex: M
Vaccine: SMALL
Symptoms: Rash
Clinical narrative: Developed rash 20 days post SPV. Resolved without complications and patient went to work. ACAM 2000 Baxter Healthcare Lot# VV04-003A on 12/02/2013.
Age: 7.0
Sex: F
Vaccine: FLU3
Symptoms: Dizziness, Immediate post-injection reaction, Pallor
Clinical narrative: Child complained of dizziness immediately after receiving flu vaccination; skin color pale. Recovered within 15 minutes after episode with no further complaints.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site rash
Clinical narrative: Erythema and rash at the injection site - recommended pt ice the area and take BENADRYL PRN and call office if symptoms worsened.
Age: 66.0
Sex: M
Vaccine: FLU3, PPV, VARZOS, PPV, VARZOS, FLU3, PPV, VARZOS
Symptoms: Neuropathy peripheral
Clinical narrative: (L) arm neuropathy radiating to neck. Presented w/ 2 rx for tramadol 50 mg po q 6 hour and diazepam 5 mg po BID.
Age: 66.0
Sex: M
Vaccine: FLU3, PPV, VARZOS, PPV, VARZOS, FLU3, PPV, VARZOS
Symptoms: Facial pain, Injection site reaction, Insomnia, Pain, Pain in extremity
Clinical narrative: (L) arm neuropathy radiating to neck. Presented w/ 2 rx for tramadol 50 mg po q 6 hour and diazepam 5 mg po BID.
Age: 66.0
Sex: M
Vaccine: FLU3, PPV, VARZOS, PPV, VARZOS, FLU3, PPV, VARZOS
Symptoms: Paraesthesia
Clinical narrative: (L) arm neuropathy radiating to neck. Presented w/ 2 rx for tramadol 50 mg po q 6 hour and diazepam 5 mg po BID.
Sex: M
Vaccine: FLU3
Symptoms: Death
Clinical narrative: This case was reported by a healthcare professional via sales representative and described the occurrence of death (cause unknown) in a male subject of unspecified age who was vaccinated with FLULAVAL (GlaxoSmithKline). On an unspecified date in 2013 the subject received a dose of FLULAVAL (unknown). In 2013, 2 months after vaccination with FLULAVAL, the subject experienced death (cause unknown). The subject died on an unspecified date in 2013, cause of death was not unknown. It was unknown whether an autopsy was performed.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly store. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13(MARRS#1401USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patient on 10/25/13 (MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13. VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 0/25/2013(MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA and PEDVAXHIB had been improperly stored. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 (MARRS# 1401USA000271) and 1 unspecified patient on 10/19/13. GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13 (MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1401USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013 (MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013 (MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly stored. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13, 2 unspecified patient on 10/12/13 (MARRS: 1410USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13(MARRS # 1410USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1410USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13(MARRS# 1410USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1410USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1410USA000279) and 1 unspecified patient on 10/25/2013(MARRS# 1410USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1410USA000277). PEDVAXHIB (Lot# J005670 and expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1410USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1410USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1410USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly store. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13, 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 MARRS#1401USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13 (MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1410USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 0/25/2013(MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly stored. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 (MARRS#1401USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13 (MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1401USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 and 1 unspecified patient on 0/25/2013 (MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013 (MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013 (MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly store. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13(MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1401USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 0/25/2013(MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly store. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13, 1 unspecified patient on 10/17/13(MARRS#1401USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13(MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1410USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 0/25/2013(MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Age: 11.0
Sex: F
Vaccine: FLUN3
Symptoms: Computerised tomogram thorax abnormal, Cough, Fungal infection, Hypotension, Influenza A virus test positive
Clinical narrative: A report from a literature source concerns an 11 year old female who received FLUMIST. The patient developed fever, cough, rhinorrhea, myalgia, and mild hypotension requiring hospitalization 12 days after LAIV receipt. Viral culture of a nasal swab had isolated the vaccine strain of influenza A virus on day 3 after vaccination but not on day 7. A nasal wash collected on day 13 at the time of onset of the symptoms was negative for influenza by DFA and culture, but influenza A virus was detectable by PCR. Insufficient RNA quantities prohibited further characterization. She was treated with antimicrobials and oseltamivir but remained febrile after 5 days of therapy. Multiple pulmonary nodules consistent with fungal infection were identified by computerized chest tomography on day 9 of hospitalization, and antifungal therapy was begun, fever resolved, and she was discharged from the hospital on day 11. The clinical impression at the time was probable fungal pneumonia. The event was judged to be possibly related to vaccination. Assessment of serious criteria of report: Hospitalization.
Age: 11.0
Sex: F
Vaccine: FLUN3
Symptoms: Myalgia, Pneumonia fungal, Polymerase chain reaction, Pulmonary mass, Pyrexia
Clinical narrative: A report from a literature source concerns an 11 year old female who received FLUMIST. The patient developed fever, cough, rhinorrhea, myalgia, and mild hypotension requiring hospitalization 12 days after LAIV receipt. Viral culture of a nasal swab had isolated the vaccine strain of influenza A virus on day 3 after vaccination but not on day 7. A nasal wash collected on day 13 at the time of onset of the symptoms was negative for influenza by DFA and culture, but influenza A virus was detectable by PCR. Insufficient RNA quantities prohibited further characterization. She was treated with antimicrobials and oseltamivir but remained febrile after 5 days of therapy. Multiple pulmonary nodules consistent with fungal infection were identified by computerized chest tomography on day 9 of hospitalization, and antifungal therapy was begun, fever resolved, and she was discharged from the hospital on day 11. The clinical impression at the time was probable fungal pneumonia. The event was judged to be possibly related to vaccination. Assessment of serious criteria of report: Hospitalization.
Age: 11.0
Sex: F
Vaccine: FLUN3
Symptoms: Rhinorrhoea
Clinical narrative: A report from a literature source concerns an 11 year old female who received FLUMIST. The patient developed fever, cough, rhinorrhea, myalgia, and mild hypotension requiring hospitalization 12 days after LAIV receipt. Viral culture of a nasal swab had isolated the vaccine strain of influenza A virus on day 3 after vaccination but not on day 7. A nasal wash collected on day 13 at the time of onset of the symptoms was negative for influenza by DFA and culture, but influenza A virus was detectable by PCR. Insufficient RNA quantities prohibited further characterization. She was treated with antimicrobials and oseltamivir but remained febrile after 5 days of therapy. Multiple pulmonary nodules consistent with fungal infection were identified by computerized chest tomography on day 9 of hospitalization, and antifungal therapy was begun, fever resolved, and she was discharged from the hospital on day 11. The clinical impression at the time was probable fungal pneumonia. The event was judged to be possibly related to vaccination. Assessment of serious criteria of report: Hospitalization.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA and PEDVAXHIB had been improperly stored. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 (MARRS# 1401USA000271) and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13 and 1 unspecified patient on 10/26/13 (MARRS# 1401USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013 (MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013 (MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
Age: 22.0
Sex: F
Vaccine: TDAP, VARCEL
Symptoms: Local reaction, Pain
Clinical narrative: 22 y/o patient ref by Occ Hlth for eval of local rxn 48 hrs s/p receipt of Varicella #2 on 02DEC13 in LUE. "6"/10 pain on lifting Lt arm. No numbness or weakness in LUE. Also received Tdap in RUE on 02DEC13 w/o significant erythema, edema or warmth at Tdap injection site.
Age: 66.0
Sex: F
Vaccine: PPV
Symptoms: Cellulitis, Injection site erythema, Injection site induration, Injection site swelling, Injection site urticaria
Clinical narrative: 10 x 10 cm Large red swollen area w/hardness at bicep and posterior (L) arm. Pain and developed wheal at inj site 10 days after injection/antibiotics given for cellulitis.
Age: 66.0
Sex: F
Vaccine: PPV
Symptoms: Pain
Clinical narrative: 10 x 10 cm Large red swollen area w/hardness at bicep and posterior (L) arm. Pain and developed wheal at inj site 10 days after injection/antibiotics given for cellulitis.
Age: 75.0
Sex: M
Vaccine: PPV
Symptoms: Injection site erythema, Injection site swelling, Skin warm
Clinical narrative: Large red swollen area at inj. site, hot to touch, 8cm x 10cm.
Age: 69.0
Sex: M
Vaccine: FLU3, TDAP
Symptoms: Petechiae, Pruritus
Clinical narrative: Noticed pruritus on chest, head and legs 48 hours past administration of immunizations - On COUMADIN - petechiae in streaks (where he scratched) noted - Esp on lower legs.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Pain, Rash erythematous
Clinical narrative: Developed very large red bump, about 4" in diameter, and red rash encompassing entire area from my elbow to almost my arm pit.  Sharp throbbing pain at area.  Shooting pain in my armpit down thru my body.  Arm painful to move. Hurts badly to touch.  Red area swollen as well.
Age: 90.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash generalised, Rash vesicular, White blood cell count decreased
Clinical narrative: DIFFUSE VESICULAR RASH, INITIALLY ASYMPTOMATIC ONLY ON TRUNK BUT EVENTUALLY SPREAD TO ENTIRE BODY.
Age: 9.0
Sex: M
Vaccine: FLU3, FLU3
Symptoms: Injection site cellulitis
Clinical narrative: Cellulitis measuring 6x6.5 around flu vaccine injection site diagnosed by Dr. on 1/2/14 at 11:30 AM.  Prescribed 250 mg capsule Cephalexin 3x day for 10 days.
Age: 30.0
Sex: F
Vaccine: FLU3
Symptoms: Bruxism, Headache
Clinical narrative: Clenching of her jaw, headache (started within an hour of injection, lasted less than an hour).
Age: 3.0
Sex: M
Vaccine: DTAPIPVHIB, HEPA, PPV
Symptoms: Gait disturbance, Injection site erythema, Injection site movement impairment, Injection site swelling, Pain
Clinical narrative: Patient was taken to ED by parents due to increasing redness and swelling at injection site.  Patient would not walk on affected leg and complained if pain.  Treated with Tylenol and Benadryl.  Monitored for infection.
Age: 31.0
Sex: F
Vaccine: FLU3
Symptoms: Headache, Throat irritation
Clinical narrative: Headache, scratchy throat (a little delayed after shot but unknown on exact hours).
Age: 33.0
Sex: F
Vaccine: FLU3
Symptoms: Headache, Throat irritation
Clinical narrative: Headache, scratchy throat.
Age: 52.0
Sex: F
Vaccine: FLU3
Symptoms: Dry throat, Oropharyngeal pain, Pain, Pyrexia
Clinical narrative: Flu shot this morning; dry throat 1.5 hours afterward and has been feeling worse; severe sore throat, fever, body aches.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site erythema, Injection site swelling, Malaise, Nausea, Pain in extremity
Clinical narrative: Where the injection is there is a bump and it is red around the injection site for about a circle of two or three inches. I feel sick to my stomach and my arm is really sore. I just don't feel well and I am concerned about the site being red and swollen.
Age: 33.0
Sex: M
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site oedema, Injection site warmth, Rash vesicular
Clinical narrative: Redness, warmth and edema @ injection site; scattered vesicular rash to both upper extremities, face and anterior chest.
Age: 37.0
Sex: M
Vaccine: FLU3
Symptoms: Diarrhoea, Vomiting
Clinical narrative: Vomiting and diarrhea 9/13.
Age: 44.0
Sex: F
Vaccine: FLU3
Symptoms: Abdominal pain upper, Chills, Headache, Pain, Pain in extremity
Clinical narrative: Chills all night, sore arm, whole body is killing me, stomach cramps, headache.
Age: 9.0
Sex: M
Vaccine: HPV4
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: Patient developed redness and swelling on and around site of injection on right arm. Area measured aproximately 4 inches in width and length.
Age: 59.0
Sex: F
Vaccine: FLU3
Symptoms: Abdominal pain upper, Diarrhoea, Fatigue, Headache
Clinical narrative: Experiencing pulsing headache, extreme fatigue, diarrhea, stomach cramps x6 days at this point.
Age: 37.0
Sex: M
Vaccine: PPV
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Large raised area around injection site approx. 3inches across, reddened, warm & painful. Applied compress.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site pain, Injection site reaction, Musculoskeletal stiffness
Clinical narrative: Pain and stiffness at injection site and in left shoulder.
Age: 58.0
Sex: M
Vaccine: HEP
Symptoms: Abdominal pain, Asthenia, Blood test, Computerised tomogram, Decreased appetite
Clinical narrative: Rash over bady, abdominal pain, weakness and loss of wanting to eat.
Age: 58.0
Sex: M
Vaccine: HEP
Symptoms: Rash generalised
Clinical narrative: Rash over bady, abdominal pain, weakness and loss of wanting to eat.
Age: 46.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Left deltoid red, hot, sore, and swollen.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Herpes zoster diagnosis in herpes zoster vaccine recipient. Diagnosed by Dr. at Health Center. Acyclovir x 7 days. Duration was less than 4 weeks. Also visited an ophthalmologist. Unilateral, 1 dermatome.
Age: 1.0
Sex: M
Vaccine: FLU3, HEPA, MMR, PNC13
Symptoms: Decreased activity, Hypersomnia, Hypophagia, Pyrexia, Somnolence
Clinical narrative: Generally healthy and well today.  Parents mention that after the last appt when he got the MMR, Influenza, PCV, and Hep A vaccine he got very very sleepy for 3 days.  Did have fever between 100-101 for 48 hours but the main symptom was that he pretty much slept all day for 3 days with no play and no eating though did nurse.  Did nurse from time to time.  She was just about to bring him in when he perked up.   Once those Sx resolved, he was back to his normal self with perfectly normal sleep/wake cycles.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Laboratory test, Muscular weakness, Myalgia, Urinary tract infection
Clinical narrative: Patient called on 12/04/2013 to say she started on 11/16/2013 having muscle aches and weakness in hands and feet.  Was seen by PCP and Chiropractor and given pain meds.  Followed up with phone call to patient on 12/20/2013.  She states that she was diagnosed with UTI and is still having some muscle aches and weakness in her hands, arms and legs and still taking pain meds.  She states that MD did not say whether he thought her problems were related to flu vaccine or not.
Age: 12.0
Sex: M
Vaccine: HEP, HEPA, TDAP
Symptoms: Grand mal convulsion
Clinical narrative: Tonic Clonic Seizure.
Age: 40.0
Sex: F
Vaccine: FLUX
Symptoms: Activities of daily living impaired, Immediate post-injection reaction, Injected limb mobility decreased, Injection site bruising, Injection site pain
Clinical narrative: Immediately with flu vaccine injection, I felt a rushing pain at the injection site (left upper arm). Since then, I have had increasing pain in my upper arm (shoulder area). It is difficult to get dressed & raise my arm above my head in certain directions. I also still feel pain like a bruise at the injection site when I touch it. All of these symptoms are still felt as of today, 1/2/14 almost one month post vaccine.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Flank pain, Headache, Herpes zoster, Influenza like illness, Nausea
Clinical narrative: Headache and pain like kidney stone on right side. Flu-like symptoms and nausea the next day. Fever. At 2:00 AM 1/2 woke with rash where pain was.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia, Rash
Clinical narrative: Headache and pain like kidney stone on right side. Flu-like symptoms and nausea the next day. Fever. At 2:00 AM 1/2 woke with rash where pain was.
Age: 64.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Inflammation, Pruritus, Skin warm
Clinical narrative: Woke up & found dark red & inflamed cirle about 2 inches in diameter. By next morning, 1/2, it was still red & hot & redness was spreading out to about 5 inches in diameter. Still itchy too.
Age: 19.0
Sex: F
Vaccine: FLU3
Symptoms: Dizziness, Dyspnoea, Lip swelling, Throat irritation
Clinical narrative: Scratchy throat, dizziness, faint feeling. Progressing to lip swelling and difficulty breathing.